MedTrace Logo

Study of Squalamine Lactate for the Treatment of Macular Edema Related to Retinal Vein Occlusion

NCT02614937 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2015-11-25

No results posted yet for this study

Summary

This was a prospective, single center, open label, randomized study evaluating the biological effect of squalamine lactate ophthalmic solution, 0.2% combined with intravitreous ranibizumab in patients with macular edema secondary to branch, hemi-central and central retinal vein occlusion (BRVO, HRVO, CRVO).

Conditions

  • Retinal Vein Occlusion
  • Macular Edema

Interventions

DRUG

ranibizumab

0.5 mg IVT ranibizumab

DRUG

Squalamine Lactate Ophthalmic Solution, 0.2%

Squalamine Lactate Ophthalmic Solution BID

Sponsors & Collaborators

  • Cumberland Valley Retina Consultants, PC

    collaborator OTHER

  • Ohr Pharmaceutical Inc.

    lead INDUSTRY

Principal Investigators

  • John Wroblewski, MD · Cumberland Valley Retinal Consultants, Hagerstown, MD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2014-12-31
Completion
2014-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02614937 on ClinicalTrials.gov